ABBVIE (ABBV) Earnings Date & Reports
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta)... Show more
ABBV is expected to report earnings to rise 41.89% to $3.76 per share on July 24
AbbVie (ABBV) First-Quarter 2026 Earnings Recap: Skyrizi and Rinvoq Fuel Revenue Beat
Key Takeaways
- AbbVie reported net revenues of $15.0 billion for the first quarter ended March 31, 2026, up 12.4% on a reported basis (10.3% operational), beating consensus estimates of $14.75 billion.
- Adjusted diluted earnings per share (EPS) came in at $2.65, a 7.7% increase year-over-year (YoY), surpassing expectations of $2.59.
- The company raised its full-year 2026 adjusted diluted EPS guidance to $14.08–$14.28 from $13.96–$14.16, despite a $0.41 EPS headwind from acquired in-process research and development (IPR&D) expenses.
- Immunology portfolio revenues reached $7.3 billion, up 16.4% reported, led by Skyrizi ($4.5 billion, +30.9%) and Rinvoq ($2.1 billion, +23.3%).
- Humira sales declined to $688 million amid ongoing patent expirations.
- Shares gained 2–3% in premarket trading following the release.
Earnings Context and Why It Matters
AbbVie's first-quarter 2026 earnings represent a critical milestone in the company's post-Humira transition. As the blockbuster immunology drug faces biosimilar competition following U.S. patent expirations, investors closely watch whether newer growth drivers like Skyrizi and Rinvoq can sustain momentum. This report underscores AbbVie's diversification across immunology, neuroscience, oncology, and aesthetics amid a competitive biopharma landscape. Strong results affirm the company's pipeline execution and operational resilience, influencing stock valuation and sector peers. For shareholders, it signals progress toward mid-single-digit revenue growth targets through 2029.
AbbVie delivered robust first-quarter results, with net revenues of $15.002 billion, exceeding Wall Street expectations and reflecting 12.4% reported growth (10.3% operational) from the prior year. GAAP diluted EPS was $0.39, down 45.8% YoY due to IPR&D charges, while adjusted diluted EPS of $2.65 rose 7.7% and topped consensus forecasts.
Immunology led with $7.290 billion in sales (up 16.4% reported), driven by Skyrizi's $4.483 billion (+30.9%) and Rinvoq's $2.119 billion (+23.3%), more than offsetting Humira's $688 million decline (-38.6%). Neuroscience grew to $2.875 billion (+26.0%), boosted by Vraylar and Botox Therapeutic. Oncology dipped slightly to $1.631 billion (-0.2%), while Aesthetics rose to $1.186 billion (+7.6%).
The company updated its 2026 guidance, lifting adjusted EPS outlook despite Q1 headwinds, signaling confidence in underlying trends.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to enhance your stock analysis workflow.
Market Reaction and Investor Sentiment
Investors welcomed the earnings beat and raised guidance, with AbbVie shares climbing 2–3% in premarket trading on April 29 and extending gains in early session trading. Sentiment turned positive as robust immunology performance and an upward EPS revision overshadowed Humira's decline and IPR&D costs, reinforcing faith in AbbVie's growth trajectory amid patent challenges.
Forward Outlook and Key Factors to Monitor
AbbVie's enhanced 2026 adjusted EPS guidance of $14.08–$14.28 reflects optimism in core growth portfolios, even after absorbing Q1 IPR&D expenses. Investors should track sustained momentum in Skyrizi and Rinvoq, which are on track to offset Humira erosion and drive immunology expansion.
Pipeline advancements remain pivotal, including label extensions for Skyrizi in inflammatory bowel disease and neuroscience launches like Vyalev. Neuroscience and aesthetics segments offer additional upside, with Vraylar and Botox showing steady gains.
Broader dynamics include biosimilar pressures on legacy products, R&D spending efficiency, and macroeconomic factors affecting pricing. Upcoming catalysts encompass clinical trial readouts and potential M&A (mergers and acquisitions) to bolster oncology. Monitoring gross margins and operational growth will provide insights into long-term sustainability.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
a research-based pharmaceutical company
Industry PharmaceuticalsMajor